X.T.L. Biopharmaceuticals Ltd. - ADR
XTLB - Insider Information
Get informed when a big investor buys or sells
+ FollowMarket Cap$677.25K
Close$
$-0.44
127.2% downside
Current Fair Value
127.2% downsideOvervalued by 127.2% based on the discounted cash flow analysis.
Insider Trades
Loading insider trades…
Congress Trades
Loading congress trades…
Share Statistics
| Market cap | $677,250.00 |
|---|---|
| Enterprise Value | $870,250.00 |
| Earnings per Share | $-17 |
| Beta | 0.45 |
| Outstanding Shares | 420,652 |
Return
| Return on Equity | 2483.46% |
|---|---|
| Return on Assets | -3800.00% |
| Return on Invested Capital | 2226.77% |
Valuation & Multiples
| P/E Ratio | -0.56 |
|---|---|
| PEG | -0.19 |
| Price to Sales | 0.81 |
| Price to Book Ratio | -1.61 |
| Enterprise Value to Revenue | 0.9 |
| Enterprise Value to EBIT | -0.15 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.31 |
| Debt to Equity | -1.06 |
Revenue Sources
No data
Last Earnings Call
Report Date
April 29, 2026
EPS Estimate
-
Consensus analyst estimateRevenue Estimate
-
Consensus analyst estimateInstitutional Put/Call Ratio
Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 1.80%▼ 15.48% |
|---|---|
| Total Invested | $20,652▼ 88.22% |
| Investors Holding | 3▼ 3.00% |
About X.T.L. Biopharmaceuticals Ltd.
2,020 employees
CEO: Joshua Levine
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to sourcing and advancing medicinal products aimed at treating autoimmune conditions. Its principal experimental compound, hCDR1, is primed for Phase II clinical studies, ...